Article Text
Abstract
Objectives We assessed comorbidities associated with psoriatic arthritis in a broad cohort of US-insured adult patients using the Truven Health Analytics MarketScan Database.
Methods Prevalence and incidence rates were assessed for 28 comorbid conditions among adult patients in the MarketScan database with a diagnosis of psoriatic arthritis and having two or more health claims for psoriatic arthritis between 1 July 2008 and 31 July 2015. Findings were compared with those of a similar, previously published analysis of patients with psoriasis.
Results Among a total of 186 552 patients with a diagnosis of psoriatic arthritis, 94 302 had two or more health claims for psoriatic arthritis during the study period and were included in the comorbidity analysis. The prevalence and incidence rates of the most common comorbidities were 47.5% and 35.0% for hyperlipidaemia, respectively; 47.3% and 31.3% for hypertension; 21.2% and 15.4% for depression; 20.2% and 13.5% for type 2 diabetes mellitus; and 16.6% and 12.4% for fibromyalgia. Patients with psoriatic arthritis had notably higher incidence rates of uveitis, fibromyalgia, osteoporosis, Crohn’s disease and non-alcoholic liver disease than patients with psoriasis.
Conclusion This observational retrospective analysis using the MarketScan database provides real-world health claims data on the prevalence and incidence of comorbidities in a large US patient population with psoriatic arthritis. The observed high cardiometabolic comorbidity rates align with those reported in the literature and may help healthcare providers in the comprehensive management of patients with psoriatic arthritis.
- psoriatic arthritis
- dmards (biologic)
- dmards (synthetic)
- cardiovascular disease
This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/
Statistics from Altmetric.com
Footnotes
Contributors KS, MP, LM, AC and PJM conceived and designed the experiments. KS, LM, AC and PJM were involved in the acquisition, analysis and interpretation of the data. All authors were involved in drafting the article or revising it critically for important intellectual content, and all authors approved the final version to be submitted for publication.
Funding This study was sponsored by Celgene Corporation. The authors received editorial support in the preparation of the manuscript from Peloton Advantage, funded by Celgene Corporation. The authors, however, wrote, directed and are fully responsible for all content and editorial decisions related to the development of the manuscript.
Competing interests KS was an employee of Celgene Corporation at the time of study conduct and had access to stocks, stock options and restricted stock units in Celgene Corporation. MP is an employee of Celgene Corporation. LM and AC were contractors for Celgene Corporation at the time of study conduct. PJM has received grant/research support and has served as a consultant for AbbVie, Amgen, Biogen Idec, Bristol-Myers Squibb, Celgene Corporation, Janssen Pharmaceutical, Eli Lilly and Company, Novartis Pharmaceuticals, Pfizer, Sun Pharmaceutical and UCB, and has served on a speakers bureau for AbbVie, Amgen, Biogen Idec, Bristol-Myers Squibb, Celgene Corporation, Genentech, Janssen Pharmaceutical, Eli Lilly and Company, Pfizer and UCB.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement All authors had full access to all the data, and the data are available upon request.